Hungarian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neurodegenerative diseases/hányás
A hivatkozás a vágólapra kerül
14 eredmények
Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol
Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol
ABHD6 and dual ABHD6/MGL inhibitors and their uses
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND
Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol
Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
FIELD OF THE INVENTION
This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also
Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
CROSS REFERENCE OT RELATED APPLICATIONS
This application is the national stage of Application No. PCT/EP2003/051042, filed 17 Dec. 2003, which application claims priority from PCT/EP2002/14837 filed 23 Dec. 2002, which are hereby incorporated by reference.
FIELD OF THE INVENTION
This invention
Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
CROSS REFERENCE TO RELATED APPLICATIONS
This nonprovisional patent application is the National Stage of International Application No.PCT/EP2003/051041, filed 17 Dec. 2003, which claims priority from PCT/EP2002/14831, filed 23 Dec. 2002, which are hereby incorporated by reference.
FIELD OF THE
Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of Application No. PCT/EP2003/051035, filed 17 Dec. 2003, which application claims priority from PCTEP2002/14835 filed 23 Dec. 2002, which are hereby incorporated by reference.
FIELD OF THE INVENTION
This invention
Benzimidazolone derivatives as CB2 receptor ligands
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
Sulfonyl benzimidazole derivatives
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
Human G-protein coupled receptor
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Antibodies immunospecific for a novel human G-protein coupled receptor family
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Aminoadamantane derivatives as therapeutic agents
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
A legteljesebb gyógynövény-adatbázis, amelyet a tudomány támogat
- Működik 55 nyelven
- A tudomány által támogatott gyógynövényes kúrák
- Gyógynövények felismerése kép alapján
- Interaktív GPS térkép - jelölje meg a gyógynövényeket a helyszínen (hamarosan)
- Olvassa el a keresésével kapcsolatos tudományos publikációkat
- Keresse meg a gyógynövényeket hatásuk szerint
- Szervezze meg érdeklődését, és naprakész legyen a hírkutatással, a klinikai vizsgálatokkal és a szabadalmakkal
Írjon be egy tünetet vagy betegséget, és olvassa el azokat a gyógynövényeket, amelyek segíthetnek, beírhat egy gyógynövényt, és megtekintheti azokat a betegségeket és tüneteket, amelyek ellen használják.
* Minden információ publikált tudományos kutatáson alapul
